Savara Inc. (NASDAQ:SVRA – Free Report) – Investment analysts at Lifesci Capital reduced their Q2 2026 earnings per share (EPS) estimates for Savara in a research note issued on Wednesday, May 13th. Lifesci Capital analyst F. Brisebois now anticipates that the company will post earnings of ($0.15) per share for the quarter, down from their prior forecast of ($0.12). The consensus estimate for Savara’s current full-year earnings is ($0.51) per share. Lifesci Capital also issued estimates for Savara’s Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.16) EPS and FY2026 earnings at ($0.62) EPS.
Other equities research analysts also recently issued research reports about the company. Oppenheimer began coverage on Savara in a report on Friday, April 24th. They issued an “outperform” rating and a $11.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a report on Tuesday, April 21st. William Blair set a $10.00 price objective on Savara in a report on Monday, March 16th. HC Wainwright reiterated a “buy” rating on shares of Savara in a report on Monday, March 16th. Finally, Wall Street Zen downgraded Savara from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $9.13.
Savara Stock Performance
SVRA stock opened at $5.27 on Friday. The company has a market cap of $1.08 billion, a P/E ratio of -9.41 and a beta of 0.28. Savara has a twelve month low of $1.89 and a twelve month high of $7.01. The company has a quick ratio of 11.85, a current ratio of 13.47 and a debt-to-equity ratio of 0.17. The business has a fifty day moving average of $5.36 and a 200-day moving average of $5.48.
Savara (NASDAQ:SVRA – Get Free Report) last released its earnings results on Wednesday, May 13th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01).
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in SVRA. Polar Capital Holdings Plc acquired a new position in Savara in the fourth quarter valued at about $50,086,000. RTW Investments LP acquired a new position in Savara in the fourth quarter valued at about $35,893,000. VR Adviser LLC grew its stake in Savara by 172.7% in the second quarter. VR Adviser LLC now owns 8,884,263 shares of the company’s stock valued at $20,256,000 after acquiring an additional 5,626,624 shares during the period. Marshall Wace LLP acquired a new position in Savara in the fourth quarter valued at about $27,496,000. Finally, Spruce Street Capital LP acquired a new position in Savara in the fourth quarter valued at about $14,539,000. 87.93% of the stock is owned by institutional investors and hedge funds.
About Savara
Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.
The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.
Further Reading
- Five stocks we like better than Savara
- Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs
- 2 Ways to Play the Big Pharma Patent Cliff
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.
